Through collaboration and sponsorship with Perkins Coie LLP, UACI is offering a sponsored year at the incubator for one deserving startup with a committed team that is working to solve a significant business or social challenge. The winning team will also receive a cash award of $15,000, which includes funding for a legal project budget. The total prize package is valued at $25,000.
Category Archives: AZBio News
C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium
TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.Continue reading
TGen-led international team identifies genes associated with suicide
Analysis of molecular-level biological changes could lead to better predictive models that would enhance assessment of suicide riskContinue reading
Two Arizona Proposals Win Phase 1 Awards in the HHS Hypertension Innovator Award Competition.
The U.S. Department of Health and Human Services (HHS) Office on Women’s Health announced the 20 winners of Phase I of the HHS Hypertension Innovator Award Competition. The competition was created to identify effective, pre-existing programs that care for people with hypertension where the programs could be or are already applied to women with hypertension who are pregnant and/or postpartum. The goal of the competition is to demonstrate sustainability and the ability to replicate and/or expand programs that provide effective monitoring and follow-up of hypertension for women who are pregnant and/or postpartum.
Congratulations go to Emagine Solutions Technology and Valleywise (in collaboration with Creighton University).Continue reading
ASU’s Biodesign Institute and Banner Health open summer opportunities for neuroscience scholars
If understanding the inner workings of the brain is on your mind, now is the time to explore the Banner-ASU Neuroscience Scholars program. Top-achieving college undergraduate and graduate science students are eligible to apply for the paid eight-week training program. Applications must be received by March 1.Continue reading
Opportunity Alert: Arizona Biomedical Research Centre Research Grants
The Arizona Biomedical Research Centre is soliciting applications from eligible entities to fill the FY2022 Research Grant Cohort. Letters of Intent for New Investigator Awards (NIA) or Investigator Grants (IG) will be accepted starting Wednesday, January 5, 2022 through 3:00 p.m. MST, January 19, 2022. Instructions and application materials can be found at https://portal.ecivis.com. The solicitation number is RFGA2022-010.Continue reading
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
For over 50 years, Novartis has developed innovative medicines to treat cardiovascular disease. Building on this legacy, I am reaching out to share the news that Novartis received approval from the U.S. Food and Drug Administration (FDA) for Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) to provide effective and sustained reduction in low-density lipid cholesterol (LDL-C), commonly referred to as “bad cholesterol,” as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality has not yet been determined but is being explored in clinical trials currently underway.
The United States spends over $125 billion on direct medical expenses for ASCVD care each year, and heart disease and stroke represent the largest medical expenditures in the country. Beyond direct healthcare costs, heart disease and stroke have been estimated to result in $138 billion annually in lost productivity.
2022 – Focused on the Year Ahead
2021 was a challenging year in many ways. It was also a year when AZBio Members stepped up to meet these challenges. As we look forward to 2022, we are focused on AZBio’s vision of Arizona becoming a top-ten bioscience state. We invite you to learn more about how you can get engaged with AZBio in 2022 and participate in focus initiatives designed to move us toward the top-ten. Continue reading
TGen-UArizona Medical School Study Points to Possible new Treatment Options for Breast Cancer Patients
Cxcl10 protein can indicate both positive and negative directions of cancer trajectoryContinue reading
HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel